1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shandong Sinobioway Biomedicine Co.,Ltd. Class A

Shandong Sinobioway Biomedicine Co.,Ltd. Class A

SSZSE:002581
4.70
CNY
-0.08
(-1.67%)
2.09BMarket Cap
Shandong Sinobioway Biomedicine Co.,Ltd. Class A
SZSE:002581
(Shenzhen Stock Exchange)

Recent

price

4.70

P/E

ratio

- -

div

yld

0.06%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.18
0.98
1.01
1.14
1.64
1.91
1.92
1.76
1.01
0.86
0.42
0.61
0.54
0.65
0.55
0.42
0.54
Revenue per Share
0.33
0.27
0.31
0.32
0.59
0.56
0.63
0.61
-0.16
0.1
-0.3
0.41
-0.02
-0.5
-0.21
-0.18
- -
Basic EPS, GAAP
0.27
0.19
- -
0.15
-0.19
0.21
0.19
0.28
-0.21
0.02
-0.07
-0.16
-0.13
-0.06
-0.02
-0.66
- -
Free Cash Flow per Basic Share
0.11
0.17
0.19
0.19
0.35
0.04
0.06
- -
0.11
0.09
0.08
0.01
0.01
0.02
- -
- -
- -
Dividend per Share
0.84
2.39
2.5
2.62
2.96
3.16
3.74
4.35
4.2
3.52
3.23
3.64
3.62
3.14
2.92
2.79
2.69
Book Value per Share
0.66
2.26
2.38
2.5
2.76
2.72
3.31
3.9
3.99
3.25
3.01
3.43
3.42
2.97
2.77
2.64
2.52
Tangible Book Value per Share
210
252
283
279
381
449
660
660
660
660
660
660
658
660
660
660
552
Basic Weighted Avg Shares
247
246
285
317
624
858
1,265
1,162
665
568
277
403
357
430
360
275
298
Sales/Revenue/Turnover
34.18
30.85
30.25
30.04
31.87
32.53
33.81
34.71
0.81
-15.6
-85.92
-47.49
-46.88
-38.78
-22.26
-51.75
- -
Operating Margin (%)
7
8
7
7
29
42
55
51
59
58
60
66
75
71
42
38
- -
Depreciation Expense
70
67
86
88
225
250
418
400
-105
63
-196
271
-15
-332
-137
-116
- -
Net Income, GAAP
16.57
15.35
14.92
14.71
11.43
14.77
8.77
15.35
- -
4.8
- -
- -
106.75
- -
- -
- -
- -
Effective Tax Rate (%)
28.42
27.19
30.23
27.75
36.04
29.16
33.02
34.4
-15.76
11.17
-70.78
67.29
-4.11
-77.35
-38.1
-42.31
- -
Profit Margin (%)
92
566
540
543
320
1,185
1,387
2,474
2,289
1,562
559
310
154
363
664
439
493
Working Capital
- -
- -
- -
- -
5
1
1
791
793
695
28
10
1
1
- -
11
21
LT Debt
177
672
704
738
902
2,144
2,527
2,931
2,845
2,401
2,203
2,481
2,480
2,174
2,022
1,946
1,869
Total Equity
39.14
15.04
12.41
12.03
19.49
13.84
17.01
12.7
- -
2.07
- -
- -
-0.09
- -
- -
- -
- -
Return on Invested Capital (%)
40.94
15.48
12.53
11.18
25.72
16.2
17.7
12.87
- -
2.52
- -
- -
-1.1
- -
- -
- -
- -
Return on Capital (%)
45.76
15.77
12.53
12.2
28.64
17.15
18.34
14.98
-3.71
2.49
-8.8
11.97
-0.61
-14.93
-6.88
-6.18
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
50
44
38
LT Borrowings
9
10
18
LT Finance Leases
3
4
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
660
660
660
Market Capitalization
4,948
4,869
2,091

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
629
556
629
Cash, Cash Equivalents & STI
220
154
243
Accounts Receivable, Net
266
249
202
Inventories
93
117
135
Total Current Liabilities
191
152
135
Payables & Accruals
- -
- -
- -
ST Debt
50
44
38
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.34%
-2.09%
-3.75%
Free Cash Flow
196.06%
533.75%
2,685.45%
Net Income, GAAP
111.37%
349.38%
-15.32%
Sales/Revenue/Turnover
-5.48%
2.92%
-23.75%
Total Cash Common Dividend
14,877.69%
80.63%
541.63%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
84
127
104
46
360
2025
35
35
62
142
275
2026
44
50
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
- -
0.19
-0.23
-0.21
2025
-0.06
-0.13
- -
-0.07
-0.18
2026
-0.08
-0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ) engages primarily in the research, development, production, and sale of biopharmaceuticals and pharmaceutical intermediates in China. The company manufactures core products including recombinant human interferon alpha-2b injections such as Anfulan and Jiefu spray, recombinant mouse nerve growth factor for injection such as Enjingfu and Encyclopedia, vaccines including a COVID-19 vaccine, and pharmaceutical intermediates like trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, and trimethyl acetate; it also provides biopharmaceutical contract research organization (CRO) and contract development and manufacturing organization (CDMO) services encompassing preclinical, clinical phase I/II/III, and commercial manufacturing along with regulatory support. Founded in 2000 and headquartered in Zibo, Shandong Province, China, with additional operations referenced in Shenzhen, the company serves domestic markets and exports to regions including the United States, Brazil, Canada, India, Japan, and South Korea, operating through subsidiaries such as Shandong Sinobioway Tianan Biotechnology Co., Ltd. Recent developments include providing CNY 7 million in funding to subsidiary Shandong Sinobioway Tianan Biotechnology Co., Ltd., receiving ethical approval for the Phase III clinical trial of its Class I innovative drug recombinant human nerve growth factor injection, and reporting semi-annual results alongside stock performance updates in 2025.